Goin’ to Morgan? So are we!
Like many of you, we are already scheduling meetings at the annual JP Morgan Healthcare Conference in San Francisco in January. This is an invitation-only event, but that doesn't stop…
Menu
Drug Development and Delivery: What’s in a name?
Our good friends at Drug Delivery Technology have, as of January, changed the name of their publication to Drug Development and Delivery. Why is this significant? We think that drug…
More on Russia…Is the US Next?
Last week we wrote about the Russian government's desire to grow their national pharmaceutical infrastructure. Our reading of the situation is that the government will "suggest" that ex-Russia companies who…
India, India, and more about India
Here is a sample of announcements from today alone regarding the pharmaceutical industry in India: First, UK-based Reckitt Benckiser is acquiring Paras Pharmaceuticals for $726 million. Paras makes a variety…
Russian government spurs pharma growth
Earlier this week, Prime Minister Putin announced that the Russian government will invest nearly $4 billion to modernize the pharmaceutical industry in Russia. Of note: Putin said he wanted 90…
Pfizer bypassing wholesalers in Oz
There is fascinating news today from Pfizer, who have decided to bypass the wholesalers in Australia and market directly to community pharmacies. To quote, "In order to develop stronger partnerships with…
EMA Publishes “Biosimilar Friendly” Guidelines
The EMA has recently published guidelines for the development of monoclonal antibody-containing biosimilar products.
Backing Biosimilars
BioPharm Int'l recently published a nice overview of where the FDA debate is on biosimilars. Highlights: There is broad support for legislation which clarifies the path for biosimilars to be…
The Indian Connection
The Indian pharmaceutical market is highly fragmented. How can pharma companies make money? PharmaTimes characterizes the market for us in summary form.
Launch evolution across Pharmerging Markets
PharmaPhorum has an excellent analysis on launch evolution across pharmerging markets, such as China, Brazil, Russia, and so forth. A few items of note: 1. The author projects that by…